ArticleBMC medicine2017

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.

Stefano MolicaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.